Irvine, Calif.-based biotech company HippoFi has debuted its new spine surgery solution, Purbridge, a new form of active bioglass.
The bioglass works to bridge new bone growth in patients after lumbar and thoracic spine fusion procedures. It shapes and holds bone into position while the patient is healing.
HippoFi's spine products, including Purbridge, are expected to reach a valuation of $18 billion by 2023.
"Purbridge is uniquely positioned to solve this critical patient need and desired surgical outcome. Our proprietary bridge-like structure has been specifically formulated by interweaving bioactive glass and our absorbent Tri-pore NanoCrystals with flexible fibers of semi-crystalline molecules of collagen," Ryan Fernan, head of Pur Biologics, said in a Nov. 23 press release. "This unique composition of three highly biocompatible elements results in a flexible and strong bioactive bridge which holds its shape and position while helping the patient heal, spanning the intended area with solid bone."